Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SynektikFRA:A2P 71 FCF Margin % is 21.32% as of Jun. 2026, which is 228% above its 10-year median of 6.50. GuruFocus rates FRA:A2P with a GF Score™ of 71/100 and a GF Value™ of €67.62 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Synektik ranks better than 87.19% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Synektik's Free Cash Flow for the
three
months ended in Jun. 2026 was €14.6 Mil. Synektik's Revenue for the
three
months ended in Jun. 2026 was €68.4 Mil. Therefore, Synektik's FCF Margin % for the quarter that ended in Jun. 2026 was 21.32%.
The historical rank and industry rank for Synektik's FCF Margin % or its related term are showing as below:
FRA:A2P'
s FCF Margin % Range Over the Past 10 Years
Min: -30.43 Med: 6.5 Max: 19.34
Current: 16.62
During the past 13 years, the highest FCF Margin % of Synektik was 19.34%. The lowest was -30.43%. And the median was 6.50%.
FRA:A2P's FCF Margin % is ranked better than 87.19% of 812
companies
in the Medical Devices & Instruments industry
Industry Median: -0.815
vs FRA:A2P: 16.62
The historical data trend for Synektik's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Synektik's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synektik FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Synektik's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Synektik's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synektik (FRA:A2P) has a FCF Margin % of 21.32% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Synektik and its competitors. This is 228% above median its historical median of 6.50. According to the industry distribution chart, Synektik ranks #104 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 12.8%.
Is Synektik's FCF Margin % too high?
Synektik's current FCF Margin % of 21.32% is 228% above median its 10-year median of 6.50. Based on the distribution chart, Synektik ranks #104 out of 812 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Synektik has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Synektik's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Synektik ranks #104 out of 812 companies for FCF Margin %. This places Synektik in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Synektik and its competitors. Synektik's current FCF Margin % is 21.32%, which is 228% above median its own 10-year median of 6.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synektik stock overvalued right now?
Based on GuruFocus' analysis, Synektik (FRA:A2P) is currently considered Modestly Overvalued. The stock's GF Value™ is €67.62, compared to a current price of €84.00 — trading 24.2% above its estimated fair value. The current FCF Margin % is 21.32%, which is 228% above median its 10-year median of 6.50. Synektik's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Synektik (FRA:A2P), the current FCF Margin % is 21.32% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synektik (FRA:A2P) Overvalued in 2026?
Based on GuruFocus' analysis, Synektik stock appears to be overvalued.
The current stock price of €84.00 is trading 24.2% above its estimated GF Value™ of €67.62.
GuruFocus considers Synektik to be Modestly Overvalued.
Key valuation signals for FRA:A2P:
FCF Margin %: 21.32% (228% above median its 10-year median of 6.50)
GF Value™: €67.62 vs. price of €84.00 (24.2% above fair value)
No single metric tells the full story. See the FRA:A2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synektik SA is a supplier of innovative products, services and IT solutions for diagnostic imaging and nuclear medicine. It sells medical devices and IT solutions used in radiology and operates research laboratory for diagnostic imaging systems and a service centre for medical equipment. Its operating segments include the sale of medical equipment used in radiology and nuclear medicine and IT solutions, Maintenance services for medical equipment as well as acceptance and specialist tests and Radiopharmaceutical production.
71GF Score
Get the complete analysis for FRA:A2P
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:A2P has been successfully added to your 
